Last updated: November 10, 2026. On November 9, 2026 the US Food and Drug Administration (FDA) ordered makers of every GLP-1 drug — including Ozempic, Wegovy, Mounjaro and Zepbound — to add a warning about a rare eye condition that can cause sudden, permanent vision loss. This guide explains what the warning means, the symptoms to watch for, and what to do at home. This guide is for information only — it is not medical advice. Always follow your doctor's guidance. Medical disclaimer: this article does not replace professional medical advice; only an eye examination by a doctor or eye specialist can confirm NAION, and any change to your medicine must be decided with your doctor.

Ozempic Vision Loss Warning 2026: FDA NAION Eye Risk & Home Care Guide

Written by Fatima Nursing Care

If you or a family member takes Ozempic, Wegovy, Mounjaro or Zepbound, there is a new warning you should know about. On Monday, November 9, 2026, the US Food and Drug Administration (FDA) ordered the makers of every GLP-1 drug to add information about a rare eye condition called NAION to the Warnings and Precautions section of their labels. NAION can cause sudden, painless vision loss in one eye — and in some cases that vision loss is permanent. The risk is rare, and the FDA has not established that these drugs cause NAION. But because the condition strikes without warning, knowing the symptoms — and acting the same day — is what matters most.

What happened on November 9, 2026?

The FDA issued a Drug Safety Communication requiring safety labelling changes for the entire class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The agency said it is "informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION)" linked to the drug class. Every maker of a GLP-1 drug must now add NAION information to the Warnings and Precautions section of its product label.

The order is class-wide — it does not single out one brand. The drugs covered include:

• Semaglutide — Ozempic, Wegovy and Rybelsus (Novo Nordisk)
• Tirzepatide — Mounjaro and Zepbound (Eli Lilly)
• Liraglutide — Victoza and Saxenda
• Dulaglutide — Trulicity
• Exenatide and the combination products Xultophy and Soliqua, plus orforglipron (Foundayo), approved in 2026

The FDA said NAION cases have been reported for every GLP-1 product currently on the market. The news was carried the same day by Reuters, USA Today and other major outlets, and "ozempic zepbound eye risk warnings" entered the top 10 of US Google Trends on the evening of November 9.

What is NAION?

NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain words, it is a kind of stroke of the optic nerve — the cable that carries pictures from your eye to your brain. Blood flow to the front of the optic nerve drops, and the nerve is damaged. The FDA describes it as "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss". The agency says the underlying cause "is not completely understood".

NAION usually affects one eye, and it usually affects people aged 50 or older. It is not the same as diabetic retinopathy — a different eye disease that can affect people with diabetes, and which GLP-1 labels already warned about. NAION is a separate condition, and until now US labels for Ozempic, Wegovy and Zepbound did not mention it.

The FDA began its review after a study published in July 2024 in JAMA Ophthalmology reported an association between semaglutide and NAION. The agency said that study had "several limitations" but decided the potential risk needed a closer look. European regulators moved earlier: in June 2025 the European Medicines Agency's safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year, and the UK medicines regulator added NAION as a very rare side effect of semaglutide in February 2026.

Ozempic vision loss symptoms to watch for

The FDA lists the symptoms of NAION as follows. If you notice any of them, contact your doctor or an eye specialist the same day:

• Sudden, painless loss of vision in one eye — often first noticed when you wake up in the morning
• Blurred or missing parts of your vision — a dark patch, a blind spot, or tunnel vision
• Part of your view going dim or missing — for example the top or bottom half of what you see
• Colours looking washed out or distorted in one eye
• Reduced central sharpness — hazy or blurry spots in the middle of your vision

How big is the risk? What the numbers actually say

The honest answer is that the risk is rare, and the evidence is still developing. The FDA was careful to say it has not determined that GLP-1 drugs cause NAION — it identified a potential increased risk. Here is what the agency's review actually found:

• 126 randomised controlled trials with 134,253 patients and 288,879 person-years of exposure were pooled. Investigators found 15 probable NAION cases: 10 among patients taking GLP-1 drugs and 5 among patients on a placebo. That equals 6.4 cases per 100,000 person-years for GLP-1 users, compared with 3.8 per 100,000 in comparison groups — a difference of about 2.6 extra cases per 100,000 person-years.
• Animal studies did not identify a mechanism by which GLP-1 drugs could increase the risk, and the results of an FDA real-world study varied depending on the comparison group used.
• A large US study published in October 2026 in the Annals of Internal Medicine (researchers at Rutgers) found an extra risk of about 3 to 4 cases per 10,000 people over 18 months on GLP-1 drugs. The authors said the study does not prove the drugs cause the condition.
• Europe's estimate: NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year, according to the European Medicines Agency.
• The manufacturer disagrees: Novo Nordisk, which makes Ozempic and Wegovy, told Reuters it "continues to believe the data do not establish a cause-and-effect relationship" and remains confident in the medicines.

Put simply: NAION is uncommon, it also occurs in people who never take these drugs, and the extra risk — if real — is small. But because the outcome can be permanent vision loss in one eye, regulators in the US, Europe and the UK have all decided patients should be warned. That is the right balance to keep in mind: do not panic, but do not ignore a sudden change in your vision either.

Who should pay closest attention?

According to the FDA, risk factors for NAION may include smoking, diabetes, high blood pressure, sleep apnoea, anaemia and kidney disease. NAION most often affects people aged 50 or older. That matters because many people who take GLP-1 drugs for type 2 diabetes or weight management already carry one or more of these risk factors — diabetes and high blood pressure in particular.

If you are over 50, have diabetes, high blood pressure or sleep apnoea, and you take a GLP-1 drug, it is worth being extra watchful about your vision. It is also worth making sure your regular diabetic eye screening is up to date, and telling your doctor about any eye problems — past or present — at your next appointment.

What to do if you take Ozempic, Wegovy, Mounjaro or Zepbound

The FDA's advice is clear, and it is also practical:

• Do not stop your medicine on your own. The FDA advises doctors to consider stopping the drug in patients who develop NAION "unless the benefits of treatment clearly outweigh the risk" — but that decision belongs to your doctor. Stopping diabetes or weight-loss treatment suddenly can itself be harmful.
• Report any sudden vision change right away. Tell your doctor or an eye specialist the same day you notice it — do not wait for your next routine appointment.
• Know the symptoms in advance. Tell the people at home what to watch for, so someone else can notice a change if you do not.
• Keep a simple record. Note the date of each weekly injection, any new symptoms, and your blood sugar readings if your doctor asks you to check them. A short written record helps the doctor decide quickly.
• Keep your regular eye checks. People with diabetes should keep up with the eye screening their doctor recommends — it is separate from NAION, but it protects your sight in other ways.
• Do not buy GLP-1 drugs from unregulated sellers. Only use medicines prescribed by a doctor and supplied through a licensed pharmacy. Fake or compounded products carry their own serious risks — see our guide on medicine overuse and safe use of medicines in Pakistan.

Home care for people taking a GLP-1 drug

Most people on GLP-1 treatment live at home and manage well. Good home care is mostly about routine, watching and support:

• Keep the weekly injection routine on schedule: a fixed day and time, a reminder on the phone, and a note of each dose taken. Never change the dose or skip doses without asking your doctor.
• Watch for warning signs every day: a quick vision check each morning — cover one eye at a time and notice if anything looks dim, blurred or missing — costs less than a minute and can catch a problem early.
• Support the basics: regular balanced meals, enough fluids, good sleep and keeping blood sugar and blood pressure under control, as your doctor advises.
• Keep the family informed: a spouse, child or caregiver who knows the symptoms can act fast if the patient does not notice the change themselves — especially for elderly parents living alone.

For families in Pakistan, a trained home nurse can take over the daily watching at home — keeping the injection and medicine record, checking for warning signs, supporting meals and daily routines, and giving the family time to rest — with the doctor directing the care plan. This matters most for elderly parents and for people with diabetes who need steady, careful follow-up at home.

Frequently Asked Questions

Can Ozempic cause vision loss?

The US FDA says GLP-1 drugs including Ozempic carry a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision loss in one eye. The FDA has not established that the drugs cause NAION — it calls the risk potential, and the evidence has limits. On November 9, 2026 the FDA ordered makers of all GLP-1 drugs to add NAION information to the Warnings and Precautions section of their labels.

What are the symptoms of NAION?

The FDA lists sudden, painless vision loss in one eye, often first noticed on waking; blurred or missing parts of vision, such as blind spots or tunnel vision; distorted colours; and reduced central sharpness. Any of these symptoms needs same-day medical care from a doctor or eye specialist.

Which GLP-1 drugs carry the new FDA eye warning?

The warning applies to the whole GLP-1 class: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide, the combination products Xultophy and Soliqua, and orforglipron (Foundayo). The FDA said NAION cases have been reported for every GLP-1 product currently on the market.

Should I stop taking Ozempic if I am worried about my eyes?

Do not stop a GLP-1 drug on your own. The FDA advises patients to report any sudden vision change to their doctor right away, and doctors should refer them to an eye specialist and consider stopping the drug unless the benefits clearly outweigh the risk. Stopping diabetes or weight-loss treatment suddenly can itself be harmful, so the decision must be made with your doctor.

How can home nursing help someone taking a GLP-1 drug?

A home nurse can keep the weekly injection routine on schedule, watch for warning signs such as sudden vision changes, keep a simple record of doses and symptoms to share with the doctor, and support daily routines for people with diabetes or other long-term conditions — with the doctor directing the care plan. WhatsApp +92 308 3688218 to arrange a certified nurse.

Sources

• US Food and Drug Administration — Drug Safety Communication: FDA requires safety labeling changes for GLP-1 receptor agonists due to potential risk of NAION (9 November 2026)
• European Medicines Agency — PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (6 June 2025)
• UK Medicines and Healthcare products Regulatory Agency — Drug Safety Update: Semaglutide and risk of NAION (5 February 2026)

Medical Disclaimer

This article is for general information only and is not a substitute for professional medical advice, diagnosis, or treatment. The figures in this article are reported as stated by the sources named — the US Food and Drug Administration (Drug Safety Communication, November 9, 2026), the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and the studies published in JAMA Ophthalmology and the Annals of Internal Medicine — and the situation may change as new data is published. The FDA describes the NAION risk as potential and has not established a cause-and-effect relationship. Always seek the advice of a qualified doctor with any questions about a medical condition, and never disregard professional medical advice or delay seeking it because of something you have read here. Only an eye examination by a doctor or eye specialist can confirm NAION. Any change to your medicine must be decided with your doctor. Sudden vision loss needs same-day medical care.